Fundacion Para La Investigacion Medica Aplicada (FIMA), a not-for-profit foundation part of the Center for Applied Medical Research (CIMA) of the University of Navarra based in Pamplona, Spain, and Vivet Therapeutics have formed a close collaboration involving the exclusive license to Vivet Therapeutics of FIMA’s novel proprietary AAV vector gene therapy technology to treat some liver diseases. Vivet Therapeutics and FIMA also work together on several projects to further develop this technology and perform cutting-edge research in several key liver disease areas, such as Wilson disease.
Vivet Therapeutics and its Spanish subsidiary, Vivet Therapeutics SL, are developing new innovative technology and have received a grant from the FEDER (Fonds européen de développement régional de l’Union européenne). Esta empresa ha recibido una ayuda cofinanciada al 50% por el Fondo Europeo de Desarrollo Regional a través del Programa Operativo FEDER 2014-2020 de Navarra.